- $373.37m
- $265.57m
Rezolute Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-American Express, Philip Morris, Royal Gold
U.S. RESEARCH ROUNDUP- Builders Firstsource, Eli Lilly, Northern Trust
Brief: Nantahala Capital Management LLC Reports 9.9% Passive Stake In Rezolute Inc As Of As Of Feb 29 - SEC Filing
Brief: Rezolute Says Preclinical Pharmacology Study Validates Potential Use Of RZ358 For Treatment Of Non-Islet Cell Tumor Hypoglycemia
Brief: Rezolute Got Letter From Nasdaq Notifying Co That It Has Regained Compliance With Bid Price Requirement For Continued Listing On Nasdaq
Brief: Rezolute Q2 EPS USD -0.27
Rezolute Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Rezolute Expands Leadership Team With Appointment Of Daron Evans, MS, Mba, As Chief Financial Officer
U.S. STOCKS ON THE MOVE-Bluebird bio, Cinemark Holdings, Steelcase Inc
Brief: Rezolute Initiates Phase 3 Clinical Study For RZ358 In Congenital Hyperinsulinism
Brief: Rezolute Completes Enrollment Of Its Phase 2 Study In Diabetic Macular Edema
Brief: Rezolute Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Brief: Rezolute Q1 EPS USD -0.28
Rezolute Inc expected to post a loss of 28 cents a share - Earnings Preview
Brief: Rezolute Receives Priority Medicines Eligibility From European Medicines Agency For Enhanced Regulatory Support Of RZ358 In Congenital Hyperinsulinism
Brief: Rezolute Announces Further Evidence Of RZ358’S Efficacy In Tumor-Mediated Hyperinsulinism
Rezolute Inc reports results for the quarter ended in June - Earnings Summary
Brief: Rezolute Q4 Operating Expenses USD 14.238 Million